Levofloxacin Pharmacokinetics (PK) in the Severely Obese

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00176306
Recruitment Status : Completed
First Posted : September 15, 2005
Results First Posted : October 12, 2012
Last Update Posted : October 12, 2012
Ortho-McNeil Pharmaceutical
Information provided by (Responsible Party):
Scott Morehead, University of Kentucky

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Obesity
Critical Illness
Intervention: Drug: Levofloxacin 750 mg IV

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Levofloxacin Arm Patients receive commercially available levofloxacin 750mg solution for intravnous use

Participant Flow:   Overall Study
    Levofloxacin Arm

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Levofloxacin Arm patients receiving levofloxacin

Baseline Measures
   Levofloxacin Arm 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   15 
>=65 years   0 
[Units: Years]
Mean (Standard Deviation)
 38.4  (12.8) 
[Units: Participants]
Female   7 
Male   8 
Region of Enrollment 
[Units: Participants]
United States   15 

  Outcome Measures

1.  Primary:   Area Under the Curve   [ Time Frame: 24 hours ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The number of ambulatory volunteers was low The acutely ill cohort was a heterogeneous population We remain unable to predict the precise effect of all of these different physiologic processes on drug pharmacokinetics

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Aaron Cook
Organization: University of Kentucky
phone: 8593239258

Responsible Party: Scott Morehead, University of Kentucky Identifier: NCT00176306     History of Changes
Other Study ID Numbers: CAPSS-391
CAPSS-391 ( Other Identifier: Johnson & Johnson )
First Submitted: September 12, 2005
First Posted: September 15, 2005
Results First Submitted: August 2, 2011
Results First Posted: October 12, 2012
Last Update Posted: October 12, 2012